Filters
A recent study has provided further evidence on the safety and tolerability of rapid administration of undiluted levetiracetam, including 2,500- and 4,500-mg doses.
A modified double-blind study shows the immunological superiority of high-dose (HD) over standard-dose (SD) inactivated influenza vaccine (IIV) in adults aged 50–64 years.
Preterm infants with acute kidney injury (AKI) may have poor neurodevelopmental outcomes, according to a study.
Adding perioperative enfortumab vedotin and pembrolizumab (EV + pembro) to surgery with radical cystectomy plus standard pelvic lymph node dissection (RC + PLND) significantly improves event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based therapy, based on the first interim analysis of the phase III KEYNOTE-905 study presented at ESMO 2025.
A fixed-dose four-factor prothrombin complex concentrate (4F-PCC) demonstrates both safety and efficacy for factor Xa inhibitor (FXal) reversal in patients with non-neurologic haemorrhage, according to a recent study.
A study in Singapore has provided a comprehensive update of the epidemiology of brain and spinal tumours managed surgically, helping guide future research on central nervous system (CNS) tumours.
Daily accumulated steps in longer bouts appear to result in lower mortality and cardiovascular disease (CVD) risks than steps accumulated in shorter bouts among suboptimally active adults, reveals a study.
Among patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy, those with a history of urinary tract stones appear to have poorer cancer-specific survival (CSS) and disease-free survival (DFS), according to a study.
Treatment with rituximab helps prevent relapse in adult patients with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS), as shown in a study.
For pregnant women with type 1 diabetes (T1D), the use of a closed-loop insulin system helps increase time spent in target glucose range, according to the open-label CIRCUIT trial.
